Serum Institute of India plans to manufacture 2-3 mn dosages of Oxford COVID-19 serum by end of August. The Serum Institute of India (SII) said it has in progress industrial a potential coronavirus vaccine industrialized by the University of Oxford. Conferring to a report, the Pune-based injection maker plans to manufacture two-three million doses of vaccine by end-August. Earlier this week, preliminary results of the phase1/2 trial published in the medical journal The Lancet show Oxford COVID-19 vaccine ChAdOx1 induces strong immune responses with no early wellbeing concerns. The researchers reported that the vaccine triggered a T-cell response within 14 days of vaccination and an antibody response within 28 days. T cells are white blood cells that can attack cells infected with the SARS-CoV-2 virus that causes COVID-19 disease.